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Standardization and genotype independence of methods used to quantify hepatitis C virus (HCV) RNA in
clinical specimens are necessary for accurate assessment of the role of HCV quantitation as a prognostic
marker for HCV infection and monitoring of the response to antiviral treatment. Commercially available
methods used to measure HCV loads include PCR-based (Roche Monitor) and hybridization-based (Quanti-
plex bDNA-2) methods. Recently, a new version of the Roche Monitor assay (version 2.0) has become available;
it has been modified to achieve more equal quantitation of different HCV genotypes. Consistent with previous
reports, Roche Monitor version 1.0 substantially underestimated concentrations of RNA transcripts of types
2b, 3a, 4a, 5a, and 6a and virus loads in individuals infected with genotypes 2 to 6 relative to reference tests.
However, version 2.0 achieved equivalent quantitation of each genotype over a narrow quantitative range (103
to 5 3 105 copies of RNA/ml) but significantly underestimated RNA concentrations above this range. The assay
showed an equivalent inability to quantify high levels of HCV RNA in plasma samples, and this was responsible
for the falsely narrow range of virus loads detected in HCV-infected individuals. In contrast, the Chiron
bDNA-2 assay could only measure RNA concentrations in the upper quantitative range (2 3 105 to 5 3 107
copies of RNA/ml) but showed equivalent sensitivity for genotypes 1 to 5; however, concentrations of type 6a
RNA transcripts and virus loads in clinical specimens from individuals infected with type 6a were underesti-
mated by a factor of 2 to 4. Differences were observed between PCR- and hybridization-based assays in their
relative quantitation of HCV RNA transcripts and HCV genomic RNA, which may cause problems with the use
of transcripts for interassay calibration.
Quantitation of hepatitis C virus (HCV) RNA sequences in
plasma has been used extensively as a prognostic marker for
individuals undergoing treatment with interferon and in the
subsequent monitoring of their responses. Several investigators
have found significant differences in virus load associated with
infection with different genotypes of HCV (1, 2, 10, 11, 13, 14,
18), and it had been argued that this could be one the factors
involved in genotype-specific differences in the outcome of
interferon therapy, in particular, the reduced responses of in-
dividuals infected with type 1b compared to those infected with
types 2 and 3 (5, 14, 18). Proper assessment of the effect of
HCV genotype on outcome requires a method for the quanti-
tation of viral loads in plasma that is equally sensitive for each
genotype.
We have previously investigated the genotype independence
of the Chiron bDNA assays (Quantiplex RNA assay bDNA-1)
and Quantiplex bDNA 2, Roche Monitor assay version 1.0, and
nested PCR at limiting dilution by using samples of genotypes
1, 2, and 3 (8). Significant differences in the efficiency of de-
tection of genotypes 1, 2, and 3 were observed for the bDNA-1
and Roche Monitor assays, whereas the bDNA-2 assay and the
nested PCR at limiting dilution were able to quantify the RNA
sequences of different genotypes with equal efficiencies. In the
current study, we have extended this investigation to a com-
parison of virus load measurement for genotypes 4 and 6 in the
bDNA-2, limiting-dilution PCR, and Roche Monitor version
1.0 assays and retested all of the genotypes using the new
version (version 2.0) of the Roche Monitor assay. This assay
had been modified by the manufacturer with the express in-
tention of achieving more equal quantitation of different ge-
notypes.
MATERIALS AND METHODS
Samples. Ninety-six plasma samples from HCV-infected, PCR-positive blood
donors (20 samples each of genotypes 1, 2, and 3; 19 of genotype 4; 1 of genotype
5; and 16 of genotype 6) were analyzed for HCV RNA levels. Type 4 samples
were from Middle Eastern countries, and type 6 samples were from Hong Kong.
Fresh plasma samples were aliquoted to ensure that all of the quantitative assays
were carried out on samples that had been frozen and thawed only twice. All
samples were tested with the bDNA-2, limiting-dilution PCR, and Roche Mon-
itor version 1.0 and 2.0 assays. Previously reported results for type 1, 2, and 3
samples in the bDNA-2, limiting-dilution PCR, and Roche Monitor version 1.0
assays were included in the current study for comparison, while RNA transcripts
were retested. Samples from individuals infected with HCV genotypes 4, 5, and
6 were genotyped by restriction fragment length polymorphism analysis of the 59
noncoding region (59NCR) (19). Samples were aliquoted and stored at 240°C
and were only frozen and thawed twice prior to testing.
Quantitation of HCV-infected samples. Three commercial assays for the de-
tection of HCV RNA were used, i.e., Quantiplex HCV RNA assay 2.0 or
bDNA-2 and the Roche Monitor assay versions 1.0 and 2.0. These assays were
performed in accordance with the manufacturers’ instructions. Unamplified
HCV RNA was detected in the bDNA-2 assay by capture onto the solid phase by
hybridization to oligonucleotides complementary to the 59NCR and core regions,
followed by detection and signal amplification to labelled probes. All samples
were tested with kit lot no. MMM169.
The Roche Monitor assays were based upon reverse transcription and ampli-
fication of the HCV RNA with primers from the 59NCR in the presence of an
internal control which shared primers with HCV. Both the competitor and
sample DNAs were detected by hybridization to a biotin-labelled probe, followed
by incubation with enzymatically labelled streptavidin and detection in a color-
imetric assay. Samples were tested with kit lots H0315 and G1722 (version 1.0)
and H0526 and H011 (version 2.0).
For the in-house limiting-dilution method (8, 15), viral RNA was extracted
from 100 ml of plasma by incubation with proteinase K (1 mg/ml) and sodium
dodecyl sulfate (0.55%) in the presence of poly(A) (40 mg/ml) and purified by
phenol-chloroform extraction as previously described (3). HCV RNA was re-
versed transcribed and amplified by nested PCR with primers specific for the
59NCR. Limiting dilution of cDNA was then carried out by using an assumed
efficiency of 5% for the reverse transcription step, as previously established (8,
20).
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Sequence analysis. Sequence analysis of the 59NCR was performed by cycle
sequencing in accordance with the instructions supplied with the Thermo Se-
quenase kit from Amersham International.
Quantitation of HCV RNA transcripts. HCV transcripts of all six genotypes
were provided by J. Detmer (Bayer Diagnostics, Emeryville, Calif.). The methods
used for their synthesis and quantitation have been described elsewhere (4, 7).
Briefly, to assess the quality of the preparations, HCV RNA transcripts were
electrophoresed on 1.5% formaldehyde gels and scanned on an Ambis 400
radioanalytic imager (Ambis, Inc., San Diego, Calif.). The preparations of the
HCV RNA transcripts used contained less than 3% free nucleotides and were
composed of at least 80% full-length transcripts. Three independent analytical
methods were used to quantify the transcripts. These included phosphate deter-
mination (6), measurement of A260, and hyperchromicity analysis (17). Tran-
scripts were quantified by the bDNA-2 and limiting-dilution assays and both
Roche Monitor assays.
Statistical analysis. Differences in the distribution of quantitative values be-
tween genotypes were detected by the Mann-Whitney U test. The correlation
between assays in the quantitation of HCV RNA was measured by using the
Spearman nonparametric test.
RESULTS
Quantitation of HCV by four different assays. HCV RNA in
samples from a total of 96 blood donors infected with geno-
types 1 to 6 was quantified by using the bDNA-2 assay in
replicate in accordance with the manufacturer’s instructions,
once by the Roche Monitor 1.0 and 2.0 assays and in at least
eight replicates at limiting dilution by the in-house assay (Ta-
ble 1). The cutoff sensitivity of the bDNA-2 assay was 0.2 3 106
copies of RNA per ml, whereas the Roche Monitor and lim-
iting-dilution assays had a cutoff sensitivity of approximately
1,000 copies of RNA per ml. Of 35 type 4 and 6 samples, 4
(11.4%) were below the cutoff of the bDNA-2 assay and a
different four samples were below the cutoff of the Roche
Monitor 1.0 assay, but all samples were positive by the Roche
Monitor 2.0 assay. Samples below the cutoff of each assay were
assigned the virus load of the cutoff. This approximation did
not affect the nonparametric methods used to analyze the data.
Correlations between the different assays for virus load mea-
surement were obtained. Spearman correlation coefficients
ranged from 0.706 for virus loads detected in the bDNA-2 and
limiting-dilution assays to 0.351 between Roche Monitor ver-
sions 1.0 and 2.0. Higher correlation coefficients were obtained
for samples of genotype 1 than for those of other genotypes
(0.747 for bDNA-2 with limiting dilution and 0.821 and 0.847
with Roche Monitor versions 1.0 and 2.0, 0.611 and 0.540 for
limiting dilution with Roche Monitor versions 1.0 and 2.0, and
0.714 between Roche Monitor versions 1.0 and 2.0). Correla-
tion coefficients ranged from 0.445 to 0.731 (genotype 2), from
0.432 to 0.756 (genotype 3), from 0.246 to 0.756 (genotype 4),
and from 20.313 to 0.903 (genotype 6) in pairwise compari-
sons of the quantitative results of the four assays.
Virus load and genotype. In three of the four assays, a wide
range of virus loads were observed among donors infected with
each genotype (Table 1 and Fig. 1). However, the range of
virus loads obtained by using Roche Monitor 2.0 was much
narrower than that obtained with the other assays. The median
values calculated for these distributions differed between dif-
ferent quantitation assays. For example, among the type 1
samples, median values of 3.415, 2.065, 1.041, and 0.273 were
observed for the bDNA-2, limiting-dilution, and Roche Mon-
itor version 1.0 and 2.0 methods, respectively, whereas for type
4 samples, medians of 2.239, 1.84, 0.038, and 0.147 were ob-
tained. When using the Mann-Whitney U test for pairwise
comparisons between genotypes, we observed no significant
difference in virus load between donors infected with types 1,
2, 3, and 4 when samples were analyzed with the bDNA-2 and
limiting-dilution assays. However, virus loads of type 6 samples
were lower than those of type 1 samples in bDNA-2 (median of
0.439 compared with 3.415), a difference that approached sta-
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tistical significance (P 5 0.08). However, no difference in virus
load between type 6 and 1 samples was detected by the limit-
ing-dilution assay (medians of 2.320 and 2.065, respectively;
P 5 0.787).
Differences in virus loads between genotypes were observed
with the Roche Monitor version 1.0 assay. Virus loads of non-
type 1 genotypes were significantly lower than those of the type
1 samples (P values were all #0.001), apart from the type 2
samples, where the difference did not reach statistical signifi-
cance. Small differences between genotype 1, 2, and 3 viral
loads were observed when the Roche Monitor version 2.0 assay
was used. However, type 4 samples showed statistically signif-
icantly lower levels of RNA than type 1 samples (median,
0.147; P 5 0.013) while type 6 sample RNA levels were higher
(median, 0.568; P 5 0.005).
The ratios of virus loads individually measured for each
sample by the bDNA-2 and Roche Monitor version 1.0 and 2.0
assays to those measured by the limiting-dilution assay were
calculated (Table 2). A particularly wide range of ratios were
observed with the Roche Monitor version 1.0 assay versus the
limiting-dilution assay, with values for types 3, 4, and 6 consis-
tently lower that those obtained for genotype 1 (P , 0.01). In
FIG. 1. Range of HCV RNA levels in plasma samples from blood donors infected with genotypes 1 to 6 as detected by the bDNA-2 (A), limiting-dilution (B), Roche
Monitor version 1.0 (C), and Roche Monitor version 2.0 (D) quantitative assays. The cutoff value of the bDNA-2 assay (0.2 3 106 copies/ml) is indicated.
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contrast, no significant difference in the ratios obtained for the
limiting-dilution assay with the bDNA-2 assay were observed
for genotypes 1, 2, 3, and 4 (Table 2). However, the median
ratio of genotype 6 samples to type 1 samples was 0.623, sig-
nificantly lower (P 5 0.03) than in the reference test. In con-
trast, the ratio of Roche Monitor version 2.0 to limiting-dilu-
tion assay results for type 6 samples was much higher than
those calculated for the other genotypes (2.950). These sam-
ples had been tested at a 1-in-10 dilution in the former assay
because of the limited sample volume available. Subsequent
experiments (see below) suggested that the difference in quan-
titation between samples of type 6 and those of other geno-
FIG. 2. Measurement of the absolute efficiencies of quantitative assays by using RNA transcripts of genotypes 1a, 2b, 3a, 4a, 5a, and 6a. The ratio of the amount
of HCV RNA detected by each assay to a known amount of transcript added was calculated with increasing amounts of RNA transcript to determine the linear dynamic
range of each assay.
TABLE 2. Efficiency of detection of different genotypes relative to detection by limiting-dilution assay
Genotype
(no. of samples)
Efficiency of detection by:
bDNA-2 Roche Monitor version 1 Roche Monitor version 2
Median (range) Ratio
a
(P value)b Median (range) Ratio (P value) Median (range) Ratio (P value)
1 (20) 1.155 (0.092–20.96) 0.531 (0.043–11.74) 0.103 (0.006–3.009)
2 (20) 1.401 (0.076–200.0) 1.210 (0.516)c 0.307 (0.002–5.758) 0.578 (0.330)d 0.096 (0.012–97.00) 0.932 (1.00)c
3 (20) 0.943 (0.013–20.00) 0.816 (0.850)c 0.050 (0.000–1.000) 0.094 (,0.001)d 0.084 (0.008–13.80) 0.816 (0.745)c
4 (19) 2.200 (0.075–13.25) 1.905 (0.126)c 0.036 (0.000–0.497) 0.068 (,0.001)d 0.154 (0.001–1.448) 1.495 (0.844)c
6 (16) 0.720 (0.134–1.387) 0.626 (0.030)d 0.078 (0.009–0.500) 0.147 (0.001)d 0.304 (0.019–6.467) 2.950 (0.203)c
a Ratio of efficiency of detection to that of genotype 1 samples.
b Probability of difference in efficiency of detection between genotypes (Mann-Whitney U test).
c Not significantly different from genotype 1 values.
d Significantly different from genotype 1 values (P ,0.05).
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types might not have been observed had it been possible to test
them undiluted.
Sequence analysis of the 5*NCRs of types 4 and 6. Current
GenBank entries do not provide sequence information up-
stream of the 59NCR primers used in the Roche and limiting-
dilution assays. In order to determine if sequence variation
within the binding sites of the primers used for amplification
could account for the differences in viral load detected in the
genotype 4 and 6 samples, we obtained nucleotide sequences
by PCR using a novel primer from the extreme 59 end of the
HCV genome in a heminested PCR. No sequence variability in
binding sites was detected in either the type 4 or 6 samples by
either the Roche or limiting-dilution assays.
Quantitation of HCV RNA transcripts. To compare the ab-
solute quantitations of RNA sequences provided by the differ-
ent assays, four different concentrations of RNA transcripts of
HCV genotypes 1 through 6 were analyzed by Roche Monitor
test versions 1.0 and 2.0 and the bDNA-2 and limiting-dilution
assays (Fig. 2). The results obtained for each sample were
deemed valid by the kit instructions, although both Roche
Monitor test versions 1.0 and 2.0 produced unexpectedly low
quantitation values above concentrations of 106 copies of
RNA/ml (Fig. 2) and were unable to accurately quantify sam-
ples with greater than 106 HCV RNA copies per ml. In con-
trast, the bDNA-2 assay was relatively accurate in detecting
HCV RNA levels over a range of transcript concentrations of
5 3 105 to 5 3 107 but was unable to detect HCV RNA levels
below the stated quantitation limit of 2 3 105 copies/ml. The
assay was less sensitive toward genotype 6a transcripts in com-
parison with the other genotypes. Surprisingly, HCV RNA
levels detected with the in-house limiting-dilution assay were
consistently higher than the amount of HCV RNA transcript
FIG. 3. Efficiencies of detection of HCV by the Roche Monitor version 2.0 and limiting-dilution assays for genotypes 1 (A), 2 (B), 3 (C), and 4 (D). Five samples
of each genotype were tested undiluted and diluted to n 3 104 according to the viral load calculated by limiting dilution to within the dynamic range of the Roche
Monitor version 2.0 assay.
TABLE 3. Comparison of quantitation of HCV RNA in clinical specimens at two dilutions by Roche Monitor version 2.0 with that by
other assays
Genotype
(no. of samples)
Median virus load, range (106 RNA copies/ml)
bDNA-2 Limiting dilution Roche Monitorversion 1.0
Roche Monitor version 2.0
Undiluted samples Samples diluted 1:10
1 (4) 6.152 (0.296–18.12) 4.565 (0.240–7.700) 2.750 (0.130–4.000) 0.250 (0.145–0.996) 1.74 (1.07–4.66)
2 (4) 11.81 (7.560–13.26) 6.500 (1.070–24.00) 2.135 (0.210–4.600) 0.313 (0.188–0.337) 1.75 (1.56–3.61)
3 (4) 9.623 (1.063–18.60) 4.300 (1.730–17.00) 0.683 (0.066–1.500) 0.290 (0.219–0.316) 1.76 (0.956–2.10)
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added to the test for all genotypes, with the exception of
genotype 3a (within the error margin); these findings contrast
with the equivalence of virus loads between this assay and the
bDNA-2 assay when plasma samples are tested. This may have
occurred because RNA transcripts may be more efficiently
reverse transcribed than full-length HCV genomic sequences
(see Discussion).
Quantitation range of the Roche Monitor version 2.0 assay.
Following the observation of consistent underquantitation of
RNA transcripts at concentrations of .106 copies/ml, we in-
vestigated whether a similar “saturation” effect influences the
quantitation of clinical specimens. Using samples of genotypes
1, 2, and 3, we compared the viral loads detected by Roche
Monitor version 2.0 in undiluted samples with those obtained
after 1-in-10 dilution prior to testing and where the measured
virus loads were multiplied by 10 (Table 3). The values of
optical density at 450 nm (OD450) obtained with the Roche
Monitor version 2.0 assay of undiluted samples all fell within
the operating range of the assay (OD450, $0.15 and #2.0).
However, virus loads in the samples diluted 1 in 10 were
consistently higher than those of undiluted samples and were
closer to those measured by the bDNA-2 or limiting-dilution
assay. (This is consistent with the finding reported in Table 1
for higher virus loads in the type 6 samples.) For example,
samples of genotype 1 showed a median viral load ratio of
Roche Monitor version 2.0 to limiting dilution of 0.138 when
tested undiluted, compared with 0.774 for samples diluted 1 in
10.
In order to determine if the Roche Monitor assay version 2.0
was operating outside its optimal range, a different set of sam-
ples of genotypes 1, 2, 3, and 4 were diluted to an estimated
viral load of n 3 104 HCV copies per ml according to that
calculated by limiting-dilution assay and retested by Roche
Monitor version 2.0. The results obtained, once corrected for
the dilution factor, were compared to the viral loads obtained
from undiluted aliquots of the same samples (Fig. 3). Consis-
tently higher viral loads were obtained when samples were
diluted prior to testing for clinical samples with viral titers
higher than 105 to 106 HCV copies per ml of plasma.
To investigate the difference in quantitation over a wide
range of dilutions, three further samples (1 each of genotypes
1 to 3) were serially diluted and retested by the Roche Monitor
version 2.0 assay (Fig. 4; Table 4). Plotting of the ratio of the
amount of HCV RNA detected by Roche Monitor version 2.0
at various dilutions to the input, determined by limiting dilu-
tion, against the amount of HCV RNA added, showed that the
measured HCV RNA levels increased in proportion to the
dilution. For example, the type 2 sample virus load increased
from 2.94 3 105 HCV copies per ml of plasma undiluted to
1.43 3 107 HCV copies per ml at the final dilution (104.0),
FIG. 4. Three plasma samples of genotypes 1, 2, and 3 were subjected to serial dilution prior to testing by the Roche Monitor version 2.0 assay. The ratio of the
amount detected by the Roche Monitor version 2.0 assay to the amount added, according to limiting dilution (see Table 4), was plotted against the dilution factor.
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giving ratios of the amount detected to the amount added of
0.012 and 0.596, respectively. For each of the samples, the
Roche Monitor version 2.0 assay measured virus loads compa-
rable to those measured by limiting dilution only at greater-
than-100-fold dilutions.
DISCUSSION
This study is an extension of the previous study (8) which
used a range of quantitative assays to measure virus load in
individuals infected with HCV genotypes 1, 2, and 3. The
existence of genotype-specific differences in the sensitivities of
these assays, as documented for the original bDNA-1 assay (2,
4, 7) and the Roche Monitor version 1.0 assay (2), affects their
quantitative accuracy, making it difficult to properly assess
virological and host factors that influence disease severity and
response to interferon therapy and interferon-ribavirin combi-
nation therapy. For example, underestimation of the virus load
in type 2-infected individuals may lead to erroneous attribution
of the virus load to their greater response to treatment, even
though it has been documented extensively that the median
virus loads of type 1- and 2-infected individuals are similar (12,
16, 18) and that (poorly understood) virological differences
between the two genotypes contribute additionally and inde-
pendently of the virus load to the likelihood of an antiviral
response.
Among currently available commercial assays for virus load
measurement, the Roche Monitor version 1.0 competitive as-
say shows the greatest differences in sensitivity to genotypes 1
and 2 (times a factor of 9) and 3 (times a factor of 12) (8). In
the current study, correction factors of times 53 for type 4
samples and times 15 for type 6 samples might be applied to
produce values as calibrated to the limiting-dilution and
bDNA-2 assays, as proposed previously for types 2 and 3,
although such corrections are unlikely to be accurate for indi-
vidual samples (8). The new version of the Roche Monitor
assay was modified to reduce the differences in sensitivity to
non-type 1 genotypes. For low concentrations of RNA tran-
scripts, detection efficiencies were equivalent between geno-
types and produced quantitative values corresponding closely
to the amount added; these findings stand in contrast in both
aspects to those of the previous assays of type 1 to 3 transcripts
(8). However, the narrowness of the quantitative range was
demonstrated by transcripts and by testing of clinical speci-
mens at different input dilutions (Fig. 3, 4, and 5). Unfortu-
nately for clinical use, measured virus loads from clinical spec-
imens might vary over nearly 2 logs, depending on the test
concentration (Fig. 4), with no indication from the test results
of whether the virus load was correct or not. For example,
undiluted type 2 and 3 samples produced incorrect virus loads
of 2.94 3 105 and 3.16 3 105 from OD450 values of 0.515 and
0.563 (internal control values, 0.842 and 0.865) yet they met
the manufacturer’s acceptance criteria (Table 4).
Equal sensitivities for all of the genotypes in the Roche
Monitor version 2.0 assay appeared to be supported by the
equivalence in median virus loads of clinical specimens from
individuals infected with genotypes 1 to 4. However, this latter
observation is likely to also have been an artifact of the inabil-
ity to quantify higher virus loads (the median virus load of the
type 6a samples tested at a 1:10 dilution was greater than those
of the other genotypes). The extremely narrow range of quan-
titation was the probable reason for the restricted range of
virus loads measured in the clinical specimens compared with
other assays (Fig. 1) and the poor correlation coefficients with
results from other assays. The distribution of virus loads dif-
fered principally from the other assays, including the original
Roche Monitor assay, in lacking virus load values of greater
than 106/ml (Fig. 1).
In contrast to the Roche Monitor version 2.0 assay, the
bDNA-2 assay had a range of quantitation that was more
TABLE 4. Titration of three plasma samples using Roche Monitor version 2.0
Input sample (no. of RNA
copies/ml)a
Test
dilution
Sample Internal control Virus load (no. of RNA
copies/ml)Dilution OD450 Dilution OD450
Genotype 1 (7.4 3 106) 1:1 1:625 0.500 1:25 0.958 2.47 3 105
1:10 1:125 0.535 1:25 0.441 1.08 3 106
1:31.6 1:125 0.398 1:25 0.598 1.77 3 106
1:100 1:125 0.191 1:25 0.550 2.24 3 106
1:316 1:25 0.203 1:25 0.511 1.67 3 106
1:1,000 1:5 0.252 1:25 0.493 1.51 3 106
1:3,160 1:1 0.457 1:25 0.456 2.20 3 106
1:10,000 1:1 0.150 1:25 0.483 1.35 3 106
Genotype 2 (2.4 3 107) 1:1 1:625 0.515 1:25 0.842 2.94 3 105
1:10 1:125 0.781 1:25 0.626 1.30 3 106
1:31.6 1:125 0.530 1:25 0.789 2.06 3 106
1:100 1:125 0.214 1:25 0.734 2.21 3 106
1:31.6 1:125 0.150 1:25 0.731 3.89 3 106
1:1,000 1:25 0.191 1:25 0.814 3.32 3 106
1:3,160 1:5 0.314 1:25 0.525 6.92 3 106
1:10,000 1:5 0.192 1:25 0.418 1.43 3 107
Genotype 3 (1.7 3 107) 1:1 1:625 0.563 1:25 0.865 3.16 3 105
1:10 1:125 0.869 1:25 0.571 1.63 3 106
1:31.6 1:125 0.447 1:25 0.351 4.33 3 106
1:100 1:125 0.270 1:25 0.506 4.68 3 106
1:316 1:25 0.360 1:25 0.407 5.56 3 106
1:1,000 1:25 0.256 1:25 0.495 9.19 3 106
1:3,160 1:25 0.166 1:25 0.565 1.25 3 107
a Virus load in test specimens was determined by limiting dilution.
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appropriate for virus load testing of untreated study subjects,
with 85% of the test specimens having virus loads in the linear
range of the assay (2 3 105 to 5 3 107 copies/ml, as evaluated
by using the RNA transcripts). However, while several studies
have documented the equivalence of quantitation of HCV
genotypes 1, 2, and 3 (7–9), both transcripts and testing of
clinical specimens in the current study revealed a measurable
reduction in sensitivity for type 6a sequences compared with
the limiting-dilution assay (twofold to eightfold). The extent to
which type 6a samples may be underquantified requires further
investigation with a larger number of samples.
Finally, and separately from the genotype issue, quantitation
of RNA transcripts and HCV genomic RNA in clinical speci-
mens revealed subtle differences in their efficiency of detection
by PCR-based and hybridization-based assays. Absolute quan-
titation with the limiting-dilution assay requires an empirical
measurement of the efficiency of reverse transcription in order
to convert the measured frequency of cDNA sequences to an
RNA concentration. For clinical specimens, we and others
have used an efficiency of 5% as a conversion factor for HCV
(and human immunodeficiency virus type 1) PCR. In the cur-
rent study and in our previous study, a 5% efficiency of reverse
transcription leads to equivalence of virus loads to those de-
tected by the bDNA-2 assay. However, use of this value for
quantitation of RNA transcripts produced consistent overesti-
mation of the RNA concentration (apart from type 3a tran-
scripts). To obtain equivalence to the amount of RNA tran-
script actually added and to the results of the bDNA-2 assay
would necessitate a substantially greater efficiency of reverse
transcription (25% for genotypes 1a, 2b, 4a, 5a, and 6a).
Both reverse transcription efficiency and hybridization to the
probes used in the bDNA-2 assay may be influenced by the
secondary structure of the RNA target. The RNA transcripts
used for assay calibration used in this and previous studies (7,
8) were 823 bases in length and may therefore show internal
base pairing in this region different from that of full-length
sequences. Structural differences that affect the accessibility of
internal sequences to hybridization to the probes used in the
bDNA-2 assay or to reverse transcription may therefore ac-
count for the differences in relative quantitation by PCR- and
hybridization-based assays. Potentially, this could prevent the
use of subgenomic RNA transcripts for the calibration of as-
says for the quantitation of HCV genomic RNA in clinical
specimens.
In summary, this study describes the equivalent or nearly
equivalent quantitation of HCV genotypes by two commer-
cially available assays that operate over quite different ranges
of virus loads, which necessarily limits the applications for
which the respective assays could be used clinically.
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